207 related articles for article (PubMed ID: 15056149)
1. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone.
Orentreich D; Leone AS
Dermatol Surg; 2004 Apr; 30(4 Pt 1):548-51. PubMed ID: 15056149
[TBL] [Abstract][Full Text] [Related]
2. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial.
Jones DH; Carruthers A; Orentreich D; Brody HJ; Lai MY; Azen S; Van Dyke GS
Dermatol Surg; 2004 Oct; 30(10):1279-86. PubMed ID: 15458523
[TBL] [Abstract][Full Text] [Related]
3. Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment.
Reytan N; Rzany B
J Drugs Dermatol; 2008 Sep; 7(9):884-6. PubMed ID: 19112805
[TBL] [Abstract][Full Text] [Related]
4. A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus.
Reytan N; Rzany B
J Drugs Dermatol; 2008 Dec; 7(12):1169-71. PubMed ID: 19137772
[TBL] [Abstract][Full Text] [Related]
5. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
[TBL] [Abstract][Full Text] [Related]
6. Liquid injectable silicone for soft tissue augmentation.
Prather CL; Jones DH
Dermatol Ther; 2006; 19(3):159-68. PubMed ID: 16784515
[TBL] [Abstract][Full Text] [Related]
7. Ten-Year and Beyond Follow-up After Treatment With Highly Purified Liquid-Injectable Silicone for HIV-Associated Facial Lipoatrophy: A Report of 164 Patients.
Jones DH; Carruthers A; Brody HJ; Black JM; Humphrey S; Carruthers J; Wesley NO; Minokadeh A
Dermatol Surg; 2019 Jul; 45(7):941-948. PubMed ID: 30893157
[TBL] [Abstract][Full Text] [Related]
8. HIV-associated facial lipoatrophy treated with injectable silicone oil: a pilot study.
Chen F; Carruthers A; Humphrey S; Carruthers J
J Am Acad Dermatol; 2013 Sep; 69(3):431-7. PubMed ID: 23711767
[TBL] [Abstract][Full Text] [Related]
9. A comparison of lipoatrophy and aging: volume deficits in the face.
Coleman S; Saboeiro A; Sengelmann R
Aesthetic Plast Surg; 2009 Jan; 33(1):14-21. PubMed ID: 18987910
[TBL] [Abstract][Full Text] [Related]
10. Contemporary surgical management of HIV-associated facial lipoatrophy.
Funk E; Bressler FJ; Brissett AE
Otolaryngol Head Neck Surg; 2006 Jun; 134(6):1015-22. PubMed ID: 16730549
[TBL] [Abstract][Full Text] [Related]
11. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.
Loutfy MR; Raboud JM; Antoniou T; Kovacs C; Shen S; Halpenny R; Ellenor D; Ezekiel D; Zhao A; Beninger F
AIDS; 2007 May; 21(9):1147-55. PubMed ID: 17502725
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
Burgess CM; Quiroga RM
J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.
Karim RB; de Lint CA; van Galen SR; van Rozelaar L; Nieuwkerk PT; Askarizadeh E; Hage JJ
Aesthetic Plast Surg; 2008 Nov; 32(6):873-8. PubMed ID: 18551339
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.
Bechara FG; Gambichler T; Brockmeyer NH; Sand M; Altmeyer P; Hoffmann K
Dermatology; 2008; 217(3):244-9. PubMed ID: 18663308
[TBL] [Abstract][Full Text] [Related]
15. HIV facial lipoatrophy: causes and treatment options.
Jones D
Dermatol Surg; 2005 Nov; 31(11 Pt 2):1519-29; discussion 1529. PubMed ID: 16416634
[TBL] [Abstract][Full Text] [Related]
16. Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse).
Comite SL; Liu JF; Balasubramanian S; Christian MA
Dermatol Online J; 2004 Oct; 10(2):2. PubMed ID: 15530292
[TBL] [Abstract][Full Text] [Related]
17. Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy.
Ramon Y; Fodor L; Ullmann Y
Dermatology; 2007; 214(2):151-4. PubMed ID: 17341865
[TBL] [Abstract][Full Text] [Related]
18. High-density hyaluronic acid for the treatment of HIV-related facial lipoatrophy.
Pignatti M; Pedone A; Baccarani A; Guaraldi G; Orlando G; Lombardi M; De Santis G
Aesthetic Plast Surg; 2012 Feb; 36(1):180-5. PubMed ID: 21717261
[TBL] [Abstract][Full Text] [Related]
19. Injectable hyaluronic acid for the correction of HIV-associated facial lipoatrophy.
Denton AB; Tsaparas Y
Otolaryngol Head Neck Surg; 2007 Apr; 136(4):563-7. PubMed ID: 17418252
[TBL] [Abstract][Full Text] [Related]
20. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.
Silvers SL; Eviatar JA; Echavez MI; Pappas AL
Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):34S-45S. PubMed ID: 16936543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
